尽管该公司损失了Q4收入,但APG资产管理公司在Vertex制药公司的股权大幅增加。 APG Asset Management significantly increased its stake in Vertex Pharmaceuticals, despite the company missing Q4 earnings.

APG资产管理公司在Vertex制药公司的股权增加了189.7%,收购了235 265个股,将总所有权提高到359 285个股。 APG Asset Management increased its stake in Vertex Pharmaceuticals by 189.7%, acquiring 235,265 shares, boosting total ownership to 359,285 shares. 尽管缺少Q4收入估计数,但Vertex公司有一个“多价购买”评级,目标价格为509.17美元。 Despite missing Q4 earnings estimates, Vertex has a "Moderate Buy" rating with a $509.17 target price. 生物技术公司重点关注细胞纤维化治疗,并正在扩展到镰状细胞病和非类阿片疼痛管理,引导2025年收入增加9%。 The biotech company focuses on cystic fibrosis treatments and is expanding into sickle cell disease and non-opioid pain management, guiding for a 9% revenue increase in 2025.